Slingshot Biosciences, Inc. Partners With Kem-En-Tec Nordic A/S to Distribute Synthetic Cells Throughout Denmark, Sweden, Norway, Finland, and Iceland
16.6.2022 10:00:00 EEST | Business Wire | Press release
SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Kem-En-Tec Nordic A/S, Provider of Competent Bioscience products to the Nordic laboratories since 1987.
The agreement entitles Kem-En-Tec Nordic A/S to the right to distribute and resell Slingshot Bio’s products in Denmark, Sweden, Norway, Finland, and Iceland. Through Kem-En-Tec Nordic A/S’s network of customers, Slingshot Bio will be able to establish its presence in the Nordic market with the well-established presence and expertise of Kem-En-Tec Nordic A/S which has been selling into flow cytometry for many years.
“Kem-En-Tec Nordic A/S’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Kem-En-Tec Nordic A/S’s extensive knowledge in the field, prominent presence, and large customer base will help us leverage our position in the flow cytometry market,” said Jeffrey Kim, CEO & Founder.
Slingshot Bio’s synthetic cellular controls provide consistent, precise, and accurate control for research users in the flow cytometry space by mimicking blood properties as detected by flow cytometry. The ability to manufacture consistent controls for flow cytometry has been missing for decades and is now accurately reproducible with Slingshot Bio’s unique manufacturing platform. “Kem-En-Tec Nordic strongly believes that the innovative synthetic cell controls from Slingshot will be widely adopted by researchers using flow cytometry in all the Nordic countries,” said Henrik Tind Nielsen, CCO & Co-Owner at Kem-En-Tec Nordic.
About Slingshot Biosciences, Inc.
Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614006014/en/
Contact information
Slingshot Biosciences, Inc.
The Synthetic Cell Company
1250 45th St. Suite 330
Emeryville, CA 94608
510-770-6806
www.slingshotbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM and Uniphore Partner to Scale Domain-Specific AI Across Core Business Processes5.5.2026 16:15:00 EEST | Press release
Uniphore, the Business AI Company, and LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership focused on the joint development of industry- and domain-specific AI solutions that combine small language models (SLMs), AI agents, and deep domain expertise. As AI adoption matures, enterprises are shifting to smaller, purpose‑built models and agents for greater precision and control. The partnership brings this approach to core business processes with governance, security, and compliance by design. Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem and global delivery, unifying enterprise data, models, and AI agents on a secure, sovereign platform. LTM will drive industry expertise, client implementation, and AI‑led transformation, while Uniphore provides the foundation for building and fine‑tuning domain‑specific SLMs. The partnership will initially focus on banking, financial services, and insurance (BFSI), manufact
QuantWare Raises $178 Million to Build World’s Most Powerful Quantum Processors at an Industrial Scale5.5.2026 16:00:00 EEST | Press release
QuantWare, the leading industrial quantum processor company, today announced a $178 million (€152 million) Series B equity funding round following the announcement of VIO-40K™, a quantum processor architecture for 10,000 qubits, 100x larger than the state of the art today. The company is building KiloFab, the world’s largest dedicated quantum open architecture fab, increasing the company’s production capacity by 20x to meet strong global customer demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505645970/en/ QuantWare co-founders Matthijs Rijlaarsdam (CEO) and Alessandro Bruno (CTO), pictured outside of QuantWare's KiloFab facility in Delft, Netherlands. QuantWare is the only company that designs, fabricates, and integrates modular quantum processors on an open architecture at an industrial scale. Its proprietary VIO™ technology — a modular Quantum Processor Architecture — allows the creation of the world’s most pow
Tacton, Award-Winning Innovation Leader, Launches AI Product Modeling Assistant to Accelerate CPQ Implementation and Eliminate Bottlenecks5.5.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of AI Product Modeling Assistant, a new capability designed to dramatically accelerate product modeling and remove one of the most persistent barriers to CPQ success. Tacton’s AI Modeling Assistant is part of a core innovation to its CPQ platform, earning a Gold win in the 24th Annual American Business Awards for Most Innovative Tech Company of the Year. For manufacturers with highly configurable products, product modeling is often the longest and most resource-intensive phase of CPQ implementation. It determines how quickly products can be brought to market, how much of the portfolio is available at launch, and ultimately how fast organizations realize value from their CPQ investment. At the same time, many manufacturers face increasing pressure from limited modeling expertise, workforce shortages, and the retirement of experienced engineers, making it e
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 15:23:00 EEST | Press release
The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in northern Finland.” A year of major exhibitions across the city Oulu’s exhibition programme extends beyond traditional museum spaces. Art appears in unexpected places such as a shopping centre, the city hall, a cathedral and in n
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release
Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom